IGF1 C-1245T

The Anabolic Switch — IGF-1 and Your Muscle-Building Potential

Insulin-like growth factor 1 (IGF-1) is one of the most powerful anabolic hormones
in the human body. It activates the PI3K/Akt/mTOR pathway | The canonical growth
signaling cascade that controls muscle protein synthesis and hypertrophy,
stimulates satellite cell activation | Muscle stem cells that divide and fuse to
repair damage and create new muscle tissue,
and drives skeletal muscle hypertrophy in response to training. The rs35767
polymorphism sits in the promoter region of the IGF1 gene, 1,245 base pairs
upstream of the transcription start site, where it regulates how much IGF-1 your
body produces.

The A allele is associated with higher circulating IGF-1 levels compared to the C
allele, and AA carriers tend to have greater muscle mass and superior athletic
performance | Particularly in power and combined power-endurance sports like
decathlon. This variant has emerged as
one of the most replicated genetic markers for elite athletic performance.

The Mechanism

rs35767 is a regulatory variant located in the promoter region of the IGF1 gene on
chromosome 12. The T-to-C substitution at position -1245 affects transcription
factor binding and gene expression. Studies show the A allele leads to higher IGF-1
production, though the exact transcription factor interactions remain under
investigation. Some research suggests the G allele may allow binding of C/EBPD
transcription activator | A DNA-binding protein that regulates gene expression,
while other evidence indicates the A allele results in higher circulating levels
through mechanisms that may involve altered promoter activity.

Once IGF-1 is secreted (primarily by the liver in response to growth hormone), it
binds to IGF-1 receptors on muscle cells. This triggers a signaling cascade:
PI3K converts PIP2 to PIP3, activating PDK1 and Akt. Akt then phosphorylates
mTORC1, which activates ribosomal protein S6 and translation initiation factor
eIF4E, ramping up protein synthesis. Simultaneously, Akt inhibits FoxO
transcription factors, blocking the expression of muscle atrophy genes | E3
ubiquitin ligases like atrogin-1 and MuRF1 that tag muscle proteins for
degradation.

IGF-1 also activates muscle satellite cells—the stem cells responsible for muscle
repair and growth. After intense exercise or muscle damage, satellite cells
proliferate and differentiate into new myonuclei, contributing approximately
half of the muscle mass gained during hypertrophy | Based on studies using viral
IGF-1 delivery in animal models.

The Evidence

The rs35767 variant has been studied extensively in athletic populations. In a
2013 Israeli study of 87 power athletes and 78 endurance athletes | Including
international and Olympic-level competitors,
the A allele was significantly more frequent in top-level power athletes compared
to national-level athletes. Among the elite power cohort, 4.8% carried the TT
genotype versus 0% in non-athletic controls—a striking overrepresentation.

A 2022 study of decathlon athletes | Decathlon demands both power and endurance
across 10 events found the AA genotype
was significantly more prevalent among decathletes compared to other athlete groups,
and AA carriers demonstrated superior speed performance. These findings align with
the physiological role of IGF-1 in fast-twitch muscle fiber development and
force production.

A 2024 meta-analysis | Pooling data across multiple cohorts to increase
statistical power
confirmed the A allele as a favorable genetic marker for both power and endurance
athletic performance, supporting the variant's role across multiple training
modalities.

At the molecular level, a 2014 study of European adults | n=569 in discovery
cohort measured circulating IGF-1 and
found that carriers of the GG genotype (equivalent to TT on the minus strand)
had significantly higher IGF-1 levels (218 ng/ml) compared to AA carriers (190
ng/ml, p=0.007). The higher IGF-1 group also showed better insulin sensitivity,
suggesting metabolic benefits beyond muscle growth.

However, not all effects are beneficial. A Japanese longitudinal cohort of 1,506
individuals | Followed for long-term health outcomes
found that AA carriers experienced faster decline in renal function over time
compared to GG carriers, suggesting chronically elevated IGF-1 may have tradeoffs
for kidney health.

Practical Actions

If you carry one or two A alleles, you have a genetic advantage for building muscle
and responding to strength training. To capitalize on this:

Prioritize resistance training. Your elevated IGF-1 levels mean you're
biochemically primed for hypertrophy. Focus on progressive overload—gradually
increasing weight, volume, or intensity over time. AA carriers may see faster
strength gains and better recovery from high-volume training compared to CC
carriers.

Consume adequate protein. IGF-1 activates mTOR, the master regulator of protein
synthesis, but mTOR needs amino acid availability to function. Aim for 1.6-2.2
g/kg body weight daily, with post-workout protein intake | 20-40g within 2 hours
of training to maximize the
anabolic window when IGF-1 signaling is elevated.

Optimize sleep and recovery. Growth hormone (the primary driver of hepatic
IGF-1 production) peaks during deep sleep. AA carriers producing more IGF-1 may
benefit even more from adequate sleep (7-9 hours) for muscle repair and satellite
cell activation.

Consider monitoring kidney function if you're TT. While the athletic benefits
are clear, the Japanese cohort data suggests potential long-term renal effects.
If you're a TT carrier pursuing intense athletic training, periodic monitoring of
eGFR and creatinine may be prudent, especially as you age or if you have other
kidney risk factors.

Interactions

rs35767 interacts with other variants in the IGF axis. rs7136446 | An intronic
IGF1 variant has also been associated
with athletic performance and may compound with rs35767 to influence IGF-1 levels
and muscle phenotype. Similarly, rs972936 | Another IGF1 intronic variant
affects IGF-1 expression and has been linked to neurological outcomes and muscle
force production.

Beyond the IGF1 gene, interactions with the growth hormone receptor and myostatin
pathway are likely. Carriers of both the IGF1 A allele and myostatin rare R
allele | Loss-of-function variants in MSTN that reduce this muscle growth inhibitor
show even greater muscle mass and performance, suggesting an additive or synergistic
effect.

For power athletes, the combination of rs35767 TT and ACTN3 RR | Alpha-actinin-3,
the "gene for speed" may represent an
elite genetic profile for explosive strength and sprint performance.